We manually measured available waterfall plots to estimate the proportions of patients with tumor shrinkage of >30%, >10% and >0% for erlotinib and gefitinib in EGFR-mutant NSCLC patients [63,84-89], for crizotinib in NSCLC patients with EML4/ALK fusion genes [90], and for vemurafenib in malignant melanoma patients with BRAF V600E mutations [8]. Here, BRAF is linked to neoplasm.